Evidence map›Paper›PMID 31723064›Full record

Trial reportJCI insight2019

Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy.

Sharon Chinthrajah, Shu Cao, Cherie Liu, Shu-Chen Lyu, Sayantani B Sindher, Andrew Long, Vanitha Sampath, Daniel Petroni, Marco Londei, Kari C Nadeau

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JCI insight, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02920021 (Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy), which is not on this map. Cited by 94 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 3 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02920021 phase2completednot on this map

Placebo-Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy

TypeinterventionalSponsorAnaptysBio, Inc.Ran2017 to 2018Enrolled20ConditionsPeanut AllergyArmsEtokimab, Placebo
3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 3 syntheses or guidelines pooled it, 184 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Review
  6. Diverging in Vivo Immune Response Patterns After Oral Food Challenge in Peanut Allergic Adults.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  7. Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment.International journal of molecular sciences · 2025
    Review
  17. Review
  18. Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025
    Review
  19. Review
  20. Review

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sharon ChinthrajahSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Shu CaoSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Cherie LiuSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Shu-Chen LyuSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Sayantani B SindherSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Andrew LongSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Vanitha SampathSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Daniel PetroniASTHMA Inc., Clinical Research Center, Northwest Asthma and Allergy Center, University of Washington, Seattle, Washington, USA.
Marco LondeiAnaptysBio Inc., San Diego, California, USA.
Kari C NadeauSean N. Parker Center for Allergy and Asthma Research at Stanford University.
Pulmonary and Allergy Associates · USAllergy, Asthma and Clinical Research Center · USAnaBios (United States) · US

Funding

Effects of IgE Blockade on T Cells in Food AllergyR01AI140134 · NIAID · STANFORD UNIVERSITY · PI NADEAU, KARI C. · 2018 to 2021
$1.6M
NIAID NIH HHS R01 AI140134
6 · The paper itself

Abstract

BACKGROUNDIL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies.METHODSIn this 6-week placebo-controlled phase 2a study, we evaluated the safety and the ability of a single dose of etokimab to desensitize peanut-allergic adults. Participants received either etokimab (n = 15) or blinded placebo (n = 5). Clinical tests included oral food challenges and skin prick tests at days 15 and 45. Blood samples were collected for IgE levels and measurement of ex vivo peanut-stimulated T cell cytokine production.RESULTSEfficacy measurements for active vs. placebo participants at the day 15 and 45 food challenge (tolerating a cumulative 275 mg of peanut protein, which was the food challenge outcome defined in this paper) demonstrated, respectively, 73% vs. 0% (P = 0.008) to 57% vs. 0% (ns). The etokimab group had fewer adverse events compared with placebo. IL-4, IL-5, IL-9, IL-13, and ST2 levels in CD4+ T cells were reduced in the active vs. placebo arm upon peanut-induced T cell activation (P = 0.036 for IL-13 and IL-9 at day 15), and peanut-specific IgE was reduced in active vs. placebo (P = 0.014 at day 15).CONCLUSIONThe phase 2a results suggest etokimab is safe and well tolerated and that a single dose of etokimab could have the potential to desensitize peanut-allergic participants and possibly reduce atopy-related adverse events.TRIAL REGISTRATIONClinicalTrials.gov NCT02920021.FUNDINGThis work was supported by NIH grant R01AI140134, AnaptysBio, the Hartman Vaccine Fund, and the Sean N. Parker Center for Allergy and Asthma Research at Stanford University.

Indexed as

Antibodies, MonoclonalPeanut HypersensitivityAdolescentAdultCells, CulturedCytokinesDouble-Blind MethodFemaleHumansInterleukin-33MaleMiddle AgedPlacebosT-LymphocytesYoung AdultAntibodies, MonoclonalCytokinesIL33 protein, humanInterleukin-33PlacebosAllergyClinical TrialsImmunology

Identifiers

PMID31723064
PMCPMC6948865
OpenAlexW2985962552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.